Unmet clinical need in autoimmune liver diseases by Dyson JK et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Dyson JK, Webb G, Hirschfield GM, Lohse A, Beuers U, Lindor K, Jones DEJ. 
Unmet clinical need in autoimmune liver diseases. Journal of Hepatology 
2015, 62(1), 208-218. 
Copyright: 
© 2014 The Authors. Published by Elsevier under the terms of the Creative Commons Attribution License 
http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, provided the original 
author and source are credited. 
DOI link to article: 
http://dx.doi.org/10.1016/j.jhep.2014.09.010 
Date deposited:   
13/02/2015 
  
ReviewUnmet clinical need in autoimmune liver diseases
Jessica K. Dyson1, Gwilym Webb2, Gideon M. Hirschfield2,3, Ansgar Lohse4, Ulrich Beuers5,
Keith Lindor6, David E.J. Jones1,3,7,⇑
1Liver Unit, Freeman Hospital, Newcastle-upon-Tyne, UK; 2Centre for Liver Research and NIHR Biomedical Research Unit, University of
Birmingham, UK; 3UK-PBC Research Consortium, UK; 4Universitat Klinikum Eppendorf, Hamburg, Germany; 5Department
of Gastroenterology & Hepatology, Amsterdam Medical Centre, Amsterdam, Netherlands; 6Arizona State University
Medical Centre, AZ, USA; 7Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, UKSummary
Despite recent advances in understanding and treatment, there
remain significant areas of unmet clinical need in each of the
autoimmune liver diseases (AILDs). The evolving research land-
scape and emerging large patient cohorts are creating unique
opportunities to translate science into new therapies and care
pathways, with the potential to significantly improve the lives
of AILD patients. However, the areas of unmet need represent real
challenges, which need to be addressed, if this vision is to be rea-
lised. This review describes the areas of unmet need in AILD in
adults relating to diagnostic and prognostic assessment, primary
therapy, symptom management, trial design and delivery, and
structured care delivery, with the aim of focusing future research
prioritisation.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Autoimmune liver diseases (AILDs) are all rare diseases (defined
as having a prevalence <50 per 100,000 population) but result in
significant morbidity and mortality. Across primary biliary cir-
rhosis (PBC), autoimmune hepatitis (AIH), primary sclerosing
cholangitis (PSC), and IgG4-related diseases (IgG4-RD) thereJournal of Hepatology 20
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recirculating system; HCC, hepatocellular carcinoma.are significant areas of unmet need. Some are shared, others
are disease specific (Fig. 1 and Table 1). As the research land-
scape in AILD evolves in parallel with high throughput genomic,
proteomic, metagenomic and metabonomic platforms, the evo-
lution of large national and international patient cohorts is
being accompanied by opportunities to translate science into
new therapies and care pathways. Alongside this upswing in
activity, there is an opportunity to focus thoughts on the unmet
needs of patients, from the initial point of accurate and timely
diagnosis, to the management of end-stage liver disease and
co-existent symptoms. In this review we attempt to define
and delineate the areas of unmet need in AILD, which relate
principally to an improvement in primary therapy, symptom
management, trial design and delivery, and structured care
delivery.
Key Points
• In PBC, biomarkers for high risk disease, predictive 
markers of UDCA non-response and secondary 
therapies for non-responders and/or alternative first-
line therapies for patients at high risk of non-response, 
are needed
• A better understanding of the place of steroid therapy 
in overlap syndromes and for the particular role of 
budesonide is required
• In PSC, recognised primary therapy still does not 
exist and biomarkers for early stage disease, high risk 
patients, and enhanced cancer risks are needed
• In AIH, stratification criteria are required to enable 
identification of high risk patients
• In IgG4 disease, accurate diagnostic markers and 
evidence-based maintenance regimens are lacking
• In all AILDs, therapies are needed for the often life-
changing systemic symptoms, such as pruritus and 
fatigue15 vol. 62 j 208–218
PBC PSC AIH IgG4
Symptoms and care delivery
Disease modification
New drugs New endpointsNew science
Itch Fatigue Care delivery
 UDCA derivatives e.g., nor-UDCA
 Better options in treatment non-     
   response (AIH, PBC)
 Anti-neoplastic agents (PSC)
 Steroid-sparing agents (AIH, IgG4)
 Preventative and early disease-
   modifying options
 Better evidence for old drugs 
  e.g., fibrates
 Early response criteria (PBC)
 Predicting cancer risk (PSC)
 Predicting treatment non-
   response (AIH, PBC)
 Non-invasive prediction of 
   cirrhosis (PBC, PSC)
 Predicting post-transplant 
   recurrence (all)
 Proteomics
 Metabolomics
 Genomics and metagenomics
 Microbiomics
 T-cell receptor sequencing
 Improved disease models
 Novel antigen discovery
 Improved anti-pruritics (e.g., 
   ASBTi, anti-autotaxin) (PBC, PSC)
 Itch GWAS (PBC)
 Isolating causative mechanisms
 Evidence base for expensive 
   therapies e.g., MARS, nasobiliary 
   drainage 
 Identify biological correlates
 Explaining symptom variations
 Symptom measurement
 Novel agents (e.g., Rituximab in PBC) 
 Strengthening evidence base for 
    existing treatments
 Standardising basic therapy and
   diagnostic criteria (all, especially IgG4)
 Reducing corticosteroid side-effects 
(AIH, IgG4)
 Remote, patient-directed, shared 
   primary care and stratified follow-up
   (all, especially PBC)
Fig. 1. Summary of unmet needs in autoimmune liver disease. Conditions in brackets following bullet points denote areas of particular need (PBC, primary biliary
cirrhosis; PSC, primary sclerosing cholangitis; AIH, autoimmune hepatitis; IgG4, immunoglobulin G subclass 4 associated disease). Central panels show typical histological
findings on haematoxylin and eosin stained liver sections (PBC, PSC, and AIH) or haematoxylin with anti-IgG4 secondary staining (IgG4). UDCA, ursodeoxycholic acid; ASBTi,
apical sodium-dependent bile transport inhibitors.
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In PBC, a key challenge in the area of diagnosis is the significance
of anti-mitochondrial antibodies (AMA, or anti-M2 detected by
ELISA) detected in the absence of liver biochemical abnormality.
Early studies, performed on a cohort of 29 patients who under-
went liver biopsy assessment, suggested that the majority of such
AMA-positive patients with normal liver function tests (LFTs) had
histological features of mild PBC (83%), and the majority went on
to develop characteristic biochemical abnormalities (83%) or
symptoms of PBC (76%) over a prolonged follow-up. None, how-
ever, became cirrhotic or died of the complications of PBC [1].
More recent population-based studies have suggested a preva-
lence for AMA in the normal population of 0.1–1% [2–4] with
up to half of the AMA-positive subjects in the larger cohorts
having biochemical abnormality. Long-term natural history stud-
ies are required, with baseline evaluation of the population, to
identify processes and markers, associated with the subsequent
development of clinically significant PBC. This will enable
identification of the subgroup with enhanced risk of disease
development and potential preventative approaches able to
change the natural history.Journal of Hepatology 201In both PBC and PSC, specific questions arise with regard to
the issue of so-called ‘‘overlap syndromes’’ with AIH and their
diagnosis; a key question if specific therapy is to be considered
[5–7]. Each disease naturally encompasses a heterogeneous
group of patients with variations in the classical clinical, bio-
chemical, serological, and histological findings, which can lead
to difficulties in diagnosis. The classical features of AIH are ele-
vated aminotransferases, raised IgG, positive auto-antibodies
[8], and interface hepatitis with portal plasma cell infiltrate on
biopsy [9]. The histology findings, however, are not specific for
the diagnosis of AIH and the International Autoimmune Hepatitis
Group (IAIHG) states that a diagnosis of AIH should not be made
when definite bile duct pathology or granulomas are present [10].
Czaja et al. found that 24% of patients with ‘‘classical AIH’’ had
biliary changes on biopsy, including destructive cholangitis,
ductopenia, and non-destructive cholangitis [11] but concluded
on further investigation that these patients lacked the features
of PBC [12]. Conversely, the ‘‘florid duct lesion’’, classically found
in PBC, is not always present and granulomatous cholangitis
was seen in only 32% of PBC patients in one study [13]. In PSC,
the classical histology findings are portal tract inflammation
with lymphocytic infiltration in the bile ducts and ductular5 vol. 62 j 208–218 209
Table 1. Remaining challenges in autoimmune liver disease.
Disease Challenges in diagnosis
and prognosis
Challenges in therapy Challenges in 
prevention
Challenges 
in symptom 
management
Challenges in trial 
design
Challenges in 
care delivery
PBC • Biomarkers for high risk 
disease at diagnosis
• Predictive markers of 
response to UDCA applicable 
early in treatment
• Markers/models to indicate 
steroid or other immune 
therapy (over-lap/cross-over)  
• Secondary therapy for UDCA 
non-responders
• Early immunotherapy to 
change disease natural history
• Preventative therapy in at 
risk individuals (e.g., post-
transplant recurrence)
• Understanding the place 
of steroid therapy (over-lap/
cross-over)
• Recurrent disease 
post-transplant
• Primary prevention 
in high risk individuals 
(AMA +ve with normal 
LFT, first degree 
relatives, etc)
• Resistant 
pruritus
• Fatigue
• Cognitive 
impairment
• Consensus 
stratification protocols 
to identify high risk 
patients for second line 
therapy trial
• Surrogate outcome 
measures acceptable to 
regulatory bodies 
• Implementation of 
stratification criteria 
in practice enabling 
identification of high risk 
patients
• Management location 
and approach for low risk 
patients
PSC • Biomarkers for high risk 
disease at diagnosis
• Biomarkers for enhanced 
risk of cholangio-carcinoma 
development
• Effective primary therapy 
• Rationalised therapy for 
extra-hepatic stricture
• Preventative therapy to 
reduce risk of cholangio- and 
colonic carcinoma
• Preventative therapy in at 
risk individuals (eg post-
transplant recurrence)
• Recurrent disease 
post-transplant
• Primary prevention 
in high risk individuals 
(IBD)
• Resistant 
pruritus
• Fatigue
• Complexity of PSC 
types (extra- vs.
intra-hepatic) and 
stratification criteria
• Surrogate outcome 
measures acceptable to 
regulatory bodies
• Lack of primary therapy
• Approach to and delivery of 
screening for malignancy
• Management location
IgG4 
disease
• Specific diagnostic markers • Evidence-based primary 
therapy regimens
• Evidence-based 
maintenance regimens
Poorly defined • Consensus for trial 
design
• Surrogate outcome 
measures acceptable 
to regulatory bodies
• Reach for diagnostic 
activity (effectiveness of 
diagnosis)
• Management location
AIH • Biomarkers for high risk 
disease at diagnosis
• Improved response markers 
as surrogates for biopsy
• Second-line treatment 
regimes for non-/partially 
steroid responding patients
• Steroid free regimens for 
steroid intolerant patients
• Recurrent disease 
post-transplant
Poorly defined • Stratification criteria
• Surrogate outcome 
measures acceptable 
to regulatory bodies
• Implementation of 
stratification criteria 
in practice enabling 
identification of high risk 
patients
• Management location 
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proliferation [14]. However, interface hepatitis is sometimes seen
and in one study, 33% of PSC cases had histological features sim-
ilar to AIH [15]. In a potentially confusing diagnostic area, the
complete clinical picture must be considered and the IAIHG
suggests that patients should be categorized according to the
predominant disease, with ‘‘overlap syndromes’’ not being
considered as distinct diagnostic entities [7].
In terms of prognosis in PBC, the key challenge is the develop-
ment of clinical tools/markers, able to predict the risk of non-
response to ursodeoxycholic acid (UDCA), the only licensed ther-
apy for the condition, and the need for alternative therapy
approaches. Current UDCA-response assessment paradigms in
PBC rely on a minimum of one year of therapy with UDCA at ade-
quate dose. This has the effect of leaving high-risk patients, who
have little chance of response, on a failing therapy for a potentially
excessive time period. Advances in the field of therapy for hepati-
tis C (HCV) were aided by the development of early response and
non-response criteria, allowing patients and clinicians to readily
understand an individual patient’s likelihood of treatment suc-
cess, but also rapidly ‘‘triaging’’ patients according to their need
for new therapies. Prospective studies in high-risk PBC patient
populations are needed to evaluate the utility of early and interim
biochemical markers and other assessments in predicting even-
tual response. This will facilitate the earlier stratification of
patients for UDCA-response and need for second-line therapy.
The very large-scale research platforms, such as the UK PBC
national patient cohort, combine baseline assessment of large
cohorts of patients, including significant numbers of high risk
patients, and banking of key biological materials, with long-term
outcomes follow-up. This will allow both assessment of key bio-
logical processes at play in patients who subsequently fail to
respond to UDCA and the biomarkers to allow their effective iden-
tification [16]. The findings from the trials of budesonide therapy
in PBC, amongst others, suggested that some histological features,
present at disease outset, such as inflammatory grade, may be
predictive of response to budesonide/UDCA combination and
provide a pointer to the potential value of histological markers
of subsequent treatment response; further studies are needed in
this area.
The issues relating to risk stratification are more marked in
PSC than in PBC, given the current lack of any validated tools or
markers. However, there is some evidence emerging to suggest
value in the concept of alkaline phosphatase (ALP) ‘‘response’’
akin to that now established in PBC (a finding, which potentially
may also help clarify the future role of UDCA) [17]. There is a
need to both track PSC immunologically more precisely over
time, and to engender patients’ willingness and clinical insight,
to allow early disease intervention. This may need to be in place
many years (perhaps even decades) prior to advanced disease,
and the present need for transplantation. Histology may hold
clues for disease management, even if it does not offer diagnostic
advantage to patients. PSC exhibits added complexity when com-
pared to PBC, with unmet clinical need particularly relating to
extra-hepatic disease and the risk of colonic and cholangiocarci-
noma [18]. There is a need for increased knowledge, regarding
the factors pre-disposing to colonic- and cholangio-carcinoma.
We need to utilize that knowledge to develop risk prediction
markers to facilitate the effective management of at-risk patients,
using currently typically surgical approaches. Improved
understanding of the science of carcinogenesis in PSC, and the
capacity to identify at-risk individuals, may enable the futureJournal of Hepatology 201development of chemo-prevention strategies to reduce individual
risk, or at the very least allow identification of high-risk patients
in whom timely liver transplantation can be considered. At
present, standard clinical practice is based around CA19-9
measurement, conventional radiological assessment and/or
cytological assessment of bile duct brushings [19]. The a1-4
fucosyltransferase (FUT3) and a1-2 4 fucosyltransferase (FUT2)
genes determine the Lewis phenotype of patients (Lewis antigens
are components of exocrine epithelial secretions present on
erythrocyte membranes) [20,21]. In Caucasians, 7–10% of individ-
uals lack functional FUT3 and are unable to synthesize CA19-9
(compared with 22% of the African populations), potentially giv-
ing false negative results [21,22]. Those, who lack functional
FUT2 have a non-secretor phenotype and have higher levels of
CA19-9 in serum and urine, potentially giving false positive
results [23]. CA19-9 can also be elevated in benign pancreatic dis-
eases [24], including in cholestatic diseases [25]. These factors
make the use of CA19-9 as a screening tool for malignancy diffi-
cult in clinical practice. There has also been some work looking at
markers in urine for the development of cholangiocarcinoma,
which may hold promise as non-invasive tools for screening.
Metzger et al. have utilized a urine peptide marker model to
distinguish cholangiocarcinoma from PSC and benign biliary
disorders with a good accuracy (AUROC 0.87, 95% CI 0.80–0.92,
p = 0.0001, 83% sensitivity, 79% specificity) [26]. Molecular
pathology approaches, including fluorescent in situ hybridisation
(FISH) of cytological specimens for the presence of polysomy, and
lipidomics assessment of bile are amongst the other technologies
offering real promise [27,28]. However, prospective evaluation
and validation of diagnostic accuracy are required before they
are recommended for routine clinical use.
There are ongoing difficulties with diagnosing AIH, and defin-
ing the disease biologically, in terms of who has a complete or
incomplete treatment response. The IAIHG diagnostic criteria
for AIH are useful for research purposes, but are cumbersome
for routine clinical practice and may under-diagnose patients
with disease variants, which may still be responsive to therapy
[10]. Histology is key but at present morphologic appearances
of AIH cannot readily be distinguished from viral or drug-induced
liver injury (DILI). For the smaller cohort of AIH patients at risk of
ultimately requiring liver transplantation, clearer early stratifica-
tion of need for more intense therapy remains important to
define. Adverse outcomes are more likely in patients presenting
at younger ages (especially type 2 disease) and those with incom-
plete biochemical response, and subsequent disease flare-ups
[29].
IgG4-RD was first recognized in 2001 [30] and is characterized
by a dense lymphoplasmacytic infiltrate, storiform fibrosis and
obliterative phlebitis [31]. Elevated serum IgG4 levels are often
present [30] but are normal in up to 40% of patients with
biopsy-proven IgG4-related disease [32]. IgG4-RD can affect the
biliary tree causing sclerosing cholangitis. In this relatively newly
appreciated disease, diagnosis can be challenging and requires
the combined presence of the characteristic histopathological
appearances and increased numbers of IgG4 positive plasma cells
[33]. Clarification of the interrelationship between PSC and IgG4
disease is required [34]. A recently described algorithm, based on
the ratio of serum IgG4 to IgG1 has shown utility for the differen-
tial diagnosis of IgG4 disease and PSC [35]. However, this
approach requires independent validation and at present there
are no predictive markers of outcome to reliably stratify therapy5 vol. 62 j 208–218 211
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needs. The recent finding that highly expanded IgG4+ B cell
clones dominate the B cell receptor repertoire in patients with
IgG4-RD, and not in healthy or disease control patients, including
PSC, suggests that an antigen-mediated immune response is piv-
otal in the pathogenesis of IgG4 associated cholangitis (IAC) and
may be critical for the development of an accurate diagnostic
marker of IgG4-RD [36].Challenges in therapy
For a significant number of patients with AIH, PBC, and IgG4-RD,
effective, albeit inexact, primary therapy exists [37]. PSC patients,
however, lack any proven effective medical therapy [37]. Across
AILDs, different groups of patients need better primary treat-
ment, with fewer side effects, and a significant number of
patients need early stratification to novel second-line therapies.
Included among these groups are patients who are likely over-
treated, who need better recognition as having milder, more
treatment responsive disease, and in whom care can be stepped
down, increasing cost-effectiveness of the disease management.
In PBC, it is now widely accepted that the majority of patients
have a form of the disease, which is treated effectively by primary
therapy with ursodeoxycholic acid (UDCA) at 13–15 mg/kg/day
[2]. For the minority who do not respond to UDCA there is a need
to understand how UDCA works and, furthermore, what UDCA
‘‘treatment failure’’ means biologically and clinically. While
UDCA is clearly the treatment at the outset of PBC, the mecha-
nisms of treatment failure may define substrata of PBC pheno-
types with inherently different natural histories. For example,
we already recognize that ductopenia and late-stage disease
modify the response [16,38]. The key area of therapy need in
PBC, therefore, is the development of effective alternative or sec-
ond-line therapies for the significant minority of patients who
either have proven UDCA under- or non-responsive forms of
the disease [16,39–42], or could be predicted through baseline
characteristics to be at high risk of non-responding. We also need
the clinical tools with which to target those therapies effectively
in practice. Currently, clinical trials of second-line agents for PBC
generally require proven failure of UDCA as an entry criterion,
meaning that the ‘‘reach’’ of UDCA primary therapy is critical
[43,44].
A number of agents are currently under evaluation for the sec-
ond-line treatment of PBC. These divide broadly into those
targeting cholestasis and bile acid biology, and those targeting
upstream autoimmune processes, although this may represent
an over-simplification. The bile acid-based farnesoid X receptor
(FXR) agonist obeticholic acid (OCA) has recently completed
phase 2 and 3 evaluation [43,45]. There is also emerging evidence
to build on earlier anecdotal findings, supporting efficacy of the
fibrates (bezafibrate and fenofibrate); agents, which are already
becoming widely used in some countries, notably Japan, despite
their limited formal trial evidence (particularly with regard to
hard clinical end points) [44,46–48]. In the context of modifying
the immune response there are also data to support the use of
budesonide; a glucocorticoid with high first-pass metabolism in
the liver. A small study, using budesonide as add-on therapy in
patients with incomplete response to UDCA showed marginal
improvement in biochemistry but significant worsening of osteo-
porosis [49]. Other studies, combining budesonide with UDCA
(without stratification for UDCA-response) compared to UDCA212 Journal of Hepatology 201alone, showed an improvement in liver histology with combina-
tion therapy [50,51]. Combination therapy led to an improve-
ment in the disease stage of patients with higher degrees of
inflammation. The mechanism of action of budesonide may be
more complex than its simple immunomodulatory effects, with
emerging evidence to suggest that it may play a role in restoring
the ‘‘bicarbonate umbrella’’, the disruption of which is thought to
be integral to cholestatic bile duct injury [52]. It must be
remembered that budesonide should not be used in cirrhotic
patients, or those with peri-hepatic shunting, because of the high
risk of side effects in patients not protected by effective first-pass
metabolism.
Treatment paradigms in other autoimmune diseases, such as
rheumatoid arthritis, have rapidly evolved to include the use of
disease modifying anti-rheumatic drugs (DMARDs) in the earli-
est, overtly immunological phases of disease. Trials of biological
agents in PBC have proven to be disappointing thus far [53],
potentially due to targeting patients with UDCA-failure who are
perhaps already within an overtly cholestatic ‘‘downstream’’
phase of the disease. The potential for the DMARD-type approach
for the primary treatment of PBC remains largely unexplored.
There is a risk that the fundamental insights gained from geno-
mic and immunologic studies [54,55] will not be therapeutically
harnessed if additional ways of stratifying risk and biologic stage
of disease, as well as effective treatment, are not developed.
In PSC, the development and evaluation of an effective pri-
mary therapy is manifestly a high priority. The use of UDCA is
not recommended in relevant treatment guidelines because of
negative trial data relating to hard clinical end points, however,
the field has been hampered by small-scale trials, the majority
of which have been under-powered. Furthermore, there is clear
evidence that UDCA in PSC, as is the case with PBC, has significant
impact on key biological processes and serum biochemistry
[56,57]. Some clinicians feel that there may be a role for careful
use of UDCA in patients with well-compensated disease [58]
but we must not ignore that the therapeutic trials of high-dose
UDCA showed biochemical improvement but ultimately demon-
strated patient harm [59]. The contrasting data pose the question
as to whether there may be an optimal dose above the levels con-
ventionally used in PBC, but below those associated with toxicity,
which may open the way for effective use of UDCA in PSC [56]. A
further potential area of therapeutic opportunity in PSC would be
application of second-line bile acid-related therapies currently
undergoing evaluation in PBC. However, important pathophysio-
logic differences between PBC and PSC need to be recognized,
particularly bile duct obstruction and malignancy [60]. As with
PBC, the adoption of a biologic-based approach to treatments,
instead of, or in parallel to bile acid-based therapies, would
necessitate an ability to select patients at appropriate junctures
of their disease. The classic PSC phenotype of a Caucasian male
in his 40s with devastating disease is increasingly challenged
by large cohort studies expanding the disease spectrum across
severity, gender and age. The close association with inflammatory
bowel disease implies that biologic-based therapy does have
merit. In terms of extra-hepatic disease in PSC there is a need
for evidence-based therapies for the management of dominant
strictures, where there is currently clinical uncertainty as to the
relative utility of stenting and dilation therapy [60].
For IgG4-RD, most information regarding treatment is from
autoimmune pancreatitis (AIP) and current approaches are often
adapted from those used in AIH and may be sub-optimal. Most5 vol. 62 j 208–218
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patients with IgG4-RD do respond rapidly to steroid treatment
but the dose and duration of therapy are unclear, as is the need
for maintenance therapy [34,61]. As our experience of managing
IgG4-RD increases, the need for steroid-sparing agents is likely to
become clear.
As regards primary therapy in AIH, the challenges faced are
not the availability of seemingly effective therapies but their
use in practice. Outcomes are more disappointing than might
be anticipated given the apparent efficacy of treatment [62].
Effective and evidence-based second-line therapies are needed
for patients unresponsive to, intolerant of, or non-adherent with
steroid-based primary immunosuppressive therapy. Steroid-free
regimens are particularly important given that one potential
explanation for the contrast between trial data and long-term
follow-up cohort outcomes in AIH may be poor adherence to
steroid-based regimes because of issues of patient acceptability
[63]. Younger patients often find prednisolone therapy difficult
to tolerate because of weight gain and cosmetic side effects. A
sensitive and realistic approach to this issue is needed to ensure
the best long-term outcomes for patients [63]. Part of the
solution is through the structure of care delivery, but the devel-
opment of steroid-free, or at least overtly steroid-minimising,
regimes would be of significant use in appropriate patients.
Budesonide has been suggested as an alternative treatment
strategy in AIH due to the lower systemic steroid exposure asso-
ciated with it as compared to prednisolone. In a recent trial of
budesonide (9 mg/day) vs. prednisolone (40 mg/day, tapered to
10 mg/day) in selected pre-cirrhotic patients, all of whom also
received azathioprine treatment, the primary end point
(complete biochemical remission without steroid-specific side
effects) was achieved in 47% of patients given budesonide vs.
18.4% given prednisolone (p <0.001). In the budesonide group,
72% did not develop steroid side effects (vs. 46.6% with prednis-
olone, p <0.001) [64]. These benefits and their generalizability
need further clarification and the question as to whether budes-
onide has a role as primary therapy in AIH or is best considered as
an alternative therapy in patients experiencing, or at risk of expe-
riencing steroid side effects is an open one.
As yet, there is no consensus as to what defines a clear treat-
ment failure in AIH by reflection of the syndromic nature of AIH,
its diagnosis, and its relatively rare nature. We lack sufficiently
large AIH treatment centres, able to identify and escalate therapy
in a trial context, for a small but significant group of frequently
young patients. Approaches to optimize the efficacy and tolera-
bility of existing seemingly effective therapies, such as azathio-
prine, where underdosing/fear of side effects leads to non-
optimal use, may also hold utility but require wider access to
pharmacologic monitoring.
For the management of patients with overlapping features of
AILD (typically PBC or PSC with features of AIH) a key question is
when, if ever, the use of steroids and subsequent steroid-sparing
agent regimes should be considered? The advent of UDCA non-
response assessment for PBC stratification, and the use of emerg-
ing second-line therapies, directed at the cholestatic disease
phase, have left the question when the targeted use of steroids
should take place. A systematic approach, with prospective stud-
ies to understand the pathophysiology of overlap and define the
histological, serological and biochemical criteria, suggestive of a
likely steroid response, is required. Additionally, better apprecia-
tion of the effects of age on the presentation of all AILDs is
needed, as an alternative viewpoint for overlap presentationsJournal of Hepatology 201[16]. This is exemplified by the pattern of injury in children with
AIH (‘‘autoimmune sclerosing cholangitis’’), which is character-
ized by hepatitic immune injury and the apparent impact of
age, as well as gender, on the UDCA-response in PBC [6,16].
The informed development, evaluation and optimal
implementation of improved primary and second-line therapies
in AILD ultimately requires increased understanding of the
pathophysiology of the diseases. There is a need for more human
tissue-based research to demonstrate relevant mechanistic
pathways, and their activation or suppression, in vivo. The contra-
dictory findings inmurinemodels and human disease in PBCwith,
for example regard to B cell depleting therapy [65,66], suggest
that using optimized human disease-based approaches is likely
more productive for effective therapy design than attempts to
exploit inexact models, which have yielded little in terms of ther-
apeutic advance. In PBC and PSC, there is a need to understand the
pathophysiology of disease evolution, and the interrelationship
between the apparently autoimmune early disease stage and sub-
sequent cholestatic and fibrotic phases to allow effective targeting
of second-line therapies in a timely fashion [67].Development of preventative strategies
At present, the concept of disease prevention in AILD does not
have any significant clinical traction, although we believe there
may be important clinical opportunities. The most obvious area
of unmet need with regard to disease prevention is avoidance
of disease recurrence following liver transplantation [68]. In
PBC, up to 30% of patients show features suggestive of recurrence
within 5 years of transplantation [69,70]. Retrospective data sug-
gest an association with tacrolimus-based primary immunosup-
pression but there are no trial data and this knowledge has not
had any widespread impact on clinical practice [69]. At present
there is no systematic approach to reduce the risk of PBC recur-
rence whether through the modification of primary immunosup-
pressive regimes or through prophylactic use of agents such as
UDCA, used in the primary therapy of PBC. Trials are needed in
this area as long-term follow-up has suggested that the develop-
ment of recurrent disease is not the uniformly benign clinical
event it was previously thought to be; a small group of patients
run into significant clinical problems [71]. In both PSC and AIH,
recurrent disease can mirror primary disease. Graft loss due to
recurrence is a growing problem in PSC and the need for high lev-
els of immunosuppression to control the highly inflammatory
process seen in some patients can lead to significant morbidity
[70,72]. At present, there is no systematic approach to prevent
recurrence and there are no clinical trials either under way or
planned. Alongside this are even more basic questions around
transplant practice in PSC, such as the nature of the biliary
anastomosis.
A further opportunity for disease prevention in PBC comes
from the identification of high-risk individuals (such as first
degree relatives of PBC patients and people who are anti-mito-
chondrial antibody (AMA) positive but do not exhibit overt dis-
ease) [1,73]. The prevalence of AMA-positivity in first-degree
relatives of PBC patients is 13.1%, compared with 1% in controls
matched for age, sex, race and residence [74]. There is, at least
potentially, the opportunity to modify the disease process before
it becomes established. Future prevention strategies may include
avoidance of environmental triggers, identified in emerging5 vol. 62 j 208–218 213
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toxicological and epidemiological research programmes [75,76].
There are also modifiable risk factors, which appear to be related
to PBC. Smoking has been found to be a risk factor for the devel-
opment of PBC [77]. Corpechot et al. found that each pack-year
of increase in smoking intensity was associated with a 5.0% (95%
CI, 1.3–8.7%) increased likelihood of advanced fibrosis [78]. Higher
lifetime tobacco consumption (greater than or equal to 10 pack-
years) is also associated with stage 3 or 4 fibrosis [79]. Based on
the strength of the associations the authors believe that PBC
patients, and those at risk of developing PBC (first degree relatives,
AMA-positive individuals with normal liver biochemistry and PBC
patients at the point of liver transplantation) should be advised to
avoid smoking to reduce their PBC-related risk (in addition to the
other health benefits). Previous urinary tract infections (UTI) have
also been identified as a risk factor for PBC (adjusted odds ratio
[AOR] 1.511, 95% CI 1.192–1.915) in a questionnaire-based
case-control study of 1032 patients with PBC [80]. A case-control
study in general practice also found that PBC is associated with
UTI prior to diagnosis (OR 1.50 [CI 1.26–1.78]) with the strongest
relationship being seen in patients under 55 years with pyelone-
phritis in the 5 years preceding diagnosis (AOR 2.60, 95% CI
1.02–6.63) [81]. A recent meta-analysis found the pooled OR for
PBC and smoking to be 1.67 (95% CI = 1.41–1.92) and 2.02 (95%
CI = 1.40–2.65) for previous UTI [82]. Whilst most pertinent to
PBC, familial risk and prevention of AIH, PSC, and associated
autoimmune disease is equally relevant.Symptom management
The quality of life of patients with AILD is frequently significantly
impaired [83–85]. The presence of advanced disease is specifi-
cally associated with systemic symptoms, but the majority of
such impairment occurs in patients with earlier stage disease
[16]. In PBC, this impairment is usually unresponsive to conven-
tional disease therapies.
The classical PBC, PSC, and IgG4-RD cholestatic symptom is
pruritus which, if severe, can have a dramatic impact on the qual-
ity of life [86]. Relief of bile duct obstruction, if present, is the
first-line treatment, in particular for PSC and IgG4 disease
patients. Many patients require medical therapy with conven-
tional bile acid sequestrants, but tolerability and lack of efficacy
can be an issue [87]. Evidence-based second-line-therapies, such
as rifampicin and oral opiate antagonists, exist but there are sig-
nificant issues with side-effects in some patients [88,89]. The
development of better second-line therapies with fewer side-
effects, which can be used in more general clinical settings is a
clinical need. Recent work has hypothesized that potential prurit-
ogens accumulate in the circulation of cholestatic patients and
activate sensory neurons. Studies suggest that lysophosphatidic
acid (LPA) and autotaxin (the serum enzyme that converts lyso-
phosphatidylcholine into LPA) may play a critical role in pruritus
and may serve as potential targets for future therapeutic inter-
ventions [90]. There is also a phase 2 trial in progress, looking
at the effect of an apical sodium-dependent bile acid transporter
inhibitor (ASBTi) in combination with UDCA in patients with PBC
with moderate to severe pruritus (NCT01904058).
UK-PBC national cohort data suggest that the penetrance of
effective therapy for pruritus is lower than anticipated (unpub-
lished data). The authors feel this may be a reflection of the com-
plexity of treatment paradigms. ‘‘Treat and forget’’ approaches
would offer real advantages for patient management. A group214 Journal of Hepatology 201of patients are refractory to medical therapy for pruritus and
the need for novel therapies in this group is significant (trans-
plantation being a costly and limited alternative approach). There
are anecdotal reports and case series data to support the use of
physical approaches to therapy, including the molecular adsor-
bent recirculating system (MARS) and naso-biliary drainage
[91,92]. Combining data from three centres showed that MARS
leads to a significant reduction in pruritus (visual analogue scale
[VAS]: from 70.2 ± 4.8 to 20.1 ± 4.2, p <0.001) and VAS decreased
by 72% immediately after treatment and the benefit was
maintained in 51% of patients at 1-month post-treatment [93].
However, these approaches are expensive with only a limited evi-
dence basis to date. ‘‘Dummy’’-controlled trials are difficult to
undertake in this patient group and therefore an alternative form
of prospective evaluation, potentially in form of intervention reg-
istries, is required.
The other major symptom which impacts PBC patients (and to
a lesser extent PSC and AIH, although less studied and reported),
and has the greatest unmet clinical need with regard to symp-
toms, is fatigue with associated cognitive symptoms [94–96]. This
appears to be the major contributing factor to quality of life
impairment in some cohorts, and is a facet of clinical practice
unresponsive to currently effective disease-modifying therapies,
such as UDCA and liver transplantation [16,97]. It is notable that
there may be a geographic variation with emerging unpublished
data showing a North/South divide in the incidence of fatigue.
The evidence regarding the underpinning mechanism is
improving and although a clinical trial of rituximab for the treat-
ment of fatigue in PBC is ongoing (NCT01904058), no licensed
therapies are currently available in this area. Physiological mark-
ers of fatigue and cognitive impairment would enable the devel-
opment of targeted therapy and an objective response to such
therapies would be of significant utility. Fatigue in PSC appears
less marked than in PBC, and cognitive impairment (outwith the
specific situation of end-stage disease and hepatic encephalopa-
thy) is unreported. This may reflect a true difference or a lack of
investigation to the same degree as fatigue has been studied in
PBC. Similarly in AIH and IgG4-RD, the problem of fatigue may
be more significant than currently recognized, but it is also possi-
ble that the impact of fatigue in these conditions is directly related
to inflammatory activity and/or the presence of advanced liver
disease.Trial design and delivery
The issues of trial design, and in particular acceptable and feasi-
ble markers of response, are the ones which are holding back
therapeutics development in AILD. Given the typically benign
nature of PBC in older patients, and the apparent effectiveness
of UDCA in this group, it is unlikely that broad-based trials of
novel therapies in unselected patients will be either feasible or
appropriate in the future [98]. Trials of novel disease-modifying
therapies in PBC are likely to take place in the setting of stratified
populations, with agents being evaluated in identified high-risk
patients [43]. The approach, which is typically adopted in current
trials is identification of risk through failure to adequately
respond to UDCA after one year of therapy, with the potential
for wasted opportunity for enhanced therapy, whilst the year of
therapy is being monitored. An alternative approach would be
to identify enhanced risk stratification parameters at baseline
including demographic factors (young age at presentation and5 vol. 62 j 208–218
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male gender), histological parameters (a re-evaluation of the sig-
nificance of disease activity and inflammation in these terms is
warranted; an approach supported by the findings from the
budesonide trials), biochemical parameters and serological
factors (PBC-specific anti-nuclear antibody [anti-gp210] and
anti-centromere antibody) have been associated with increased
risk of non-response to UDCA and worse outcome [99,100]. Mark-
ers of high clinical risk, used for enrolment into trials of enhanced
therapy are at present limited to biochemical measures, with
inconsistencies between proposed measures. The standardization
of approaches would be of significant value. Ongoing second-line
therapy trials are utilizing improvement in composite biochemi-
cal risk scores because of the lack of other validated disease
response markers. There are practical issues of undertaking pla-
cebo-controlled trials to hard clinical end points in a disease,
which is often only slowly progressive, even in high-risk patients
[98]. Response biomarkers aligned to the nature of the disease
process and acceptable to regulatory bodies to allow rapid
approval of therapies without the need to undertake non-feasible
long-term outcome studies would be of significant use in PBC.
Histology should be reconsidered as an end point for trials in
PBC, PSC, and AIH, particularly if novel markers of fibrosis (e.g.
collagen proportionate area), or immunodiagnostics can be devel-
oped. Transient elastography (TE) measures liver stiffness as a
surrogate marker of liver fibrosis and is well-established in the
management of other chronic liver diseases [101,102]. The value
of TE in PBC has recently been shown. Floreani et al. found that TE
performs better than other non-invasive markers in PBC, with an
area under receiver operating characteristic (AUROC) of 0.89 and
0.99 for METAVIR stage PF2 and F4 fibrosis, respectively [103].
The comparator group for non-invasive tests of fibrosis for this
study did not, however, include the serum enhanced liver fibrosis
assay (ELF), which itself has significant diagnostic utility for fibro-
sis in PBC [104]. A recent study found the cut-offs forPF2 and F4
fibrosis to be 8.8 and 16.9 kPa, respectively. TE was found to be
superior to biochemical markers for the diagnosis of advanced
fibrosis and cirrhosis and an increase of 2.1 kPa/year to be asso-
ciated with an 8.4-fold increased risk of decompensation, trans-
plantation, or death (p <0.0001) [105]. The critical issue with
these non-invasive markers of disease severity, and the area of
unmet need, is the extent of their responsivity to biological
change, resulting from the actions of a therapy (the key issue in
trial outcomes). Clearly, demonstrating this property is challeng-
ing without access to therapies proven to reverse or stop fibrosis.
However, in order to allow us to answer the question definitively
in the future, it would be logical to include these modalities in tri-
als of novel prognostic therapies in PBC. TE, as with liver biopsy,
has a role in the risk stratification of patients at randomization in
therapeutic trials.
Issues with regard to trial design and delivery in PSC mirror
those in PBC. There are, however, specific additional challenges.
Better diagnostic tools are required, particularly for early disease
detection, as a lack of clear-cut diagnostic markers in routine
clinical practice complicate the design and delivery of clinical tri-
als in what are very heterogeneous patient groups. Response bio-
markers other than those involving classic biochemistry and
histological assessment are required, akin to the needs in PBC.
TE is also a valuable surrogate marker for fibrosis in PSC. A pro-
spective study, comparing TE to liver biopsy, found cut-off values
forPF2, and F4 fibrosis to be 8.6 and 14.4 kPa, respectively, with
high diagnostic accuracy. The rate of increase in liver stiffness isJournal of Hepatology 201independently linked with patient outcomes [106]. Further vali-
dation studies are required, but TE will have a likely role in the
future trial design for PSC as for PBC. In PSC, there is also a need
for longitudinal studies, to better define the radiologic course of
the disease (using repeated magnetic retrograde cholangio-
pancreatography [MRCP]) and the relationships with clinical
outcomes. This approach may lead to the identification of new
markers of disease progression for clinical trials.
The pioneering trials, which defined therapy in AIH, were con-
trolled and were associated with a high mortality rate in the con-
trols. Clearly placebo-controlled trials in AIH would now be
unethical, making trial design for novel agents in comparison to
the standard of care difficult because of the high level of efficacy
of conventional therapy in population terms. As with PBC, a strat-
ified approach with targeting trials at high-risk, unresponsive
patients is likely to be the most productive approach, but will
require definition, validation and acceptance by regulatory
bodies of criteria for high-risk/treatment non-response. As with
PBC, trials to death or transplant as the outcome-measure are
unlikely to be feasible, necessitating the identification of response
biomarkers.Structured care delivery
In all four disease areas it is likely that care delivery structures,
which have evolved little over the last 20 years, will limit the
effective delivery of optimal care in the future. The limitations
associated with existing care delivery models are likely to be fur-
ther exposed by the challenge of delivering effective second-line
therapies when these are licensed. The challenges of structured
care delivery are shared between AILD and other rare diseases,
but at present are pronounced, because unlike some rare diseases,
current therapy is in fact relatively cheap and therefore AILD is
relatively hidden on the health economic radar of hospitals and
commissioners. We believe that optimal care in all AILDs, and
the most effective use of emerging therapies, will be achieved
using structured care approaches. Incentives to evolve such
approaches may paradoxically come from the introduction of
more expensive therapies. Currently there is evidence to suggest
limitations in care for primary therapies. The universal use of
UDCA as first-line therapy for all PBC patients represents the first
stage in an emerging stratified approach to treatment. Data from
the UK-PBC national cohort suggests that an important minority
of PBC patients does not receive UDCA as primary therapy [16].
Confusing messages in the literature regarding efficacy of UDCA
may have contributed to this. A clear and simple message of the
universal use of UDCA needs to be propagated. More recent UK
data also suggest that limitations in the reach of maintenance
therapy with azathioprine may contribute to the poor long-term
outcomes identified in younger presenting AIH patients [62].
The current clinical delivery models in PBC do not typically
incorporate concepts of UDCA-response and non-response and
there is only poor awareness of the importance of assessing
response and consideration of second-line therapy amongst man-
aging clinicians [107]. This means high-risk, non-responding
patients are not being identified for evaluation, enhanced moni-
toring (appropriate, given their high risk of disease progression)
or for participation in trials of second-line therapy. Development
of a stratified care delivery model will clearly be necessary for tar-
geting of second-line therapies once they reach clinical practice.5 vol. 62 j 208–218 215
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The lack of utilisation of UDCA-response stratification in practice
also means that opportunities to reduce the care costs of low-risk
patients (UDCA-responders) through community rather than hos-
pital care are lost. At present the stratification model is not in
place for AIH but this is likely to evolve in the short-term.
In PSC, in the absence of a clearly proven effective primary
therapy, systematisation of the approach to management relates
largely on screening for cancer. Still, the definition of putative
subgroups in PSC, e.g. early stage disease, whichmight adequately
respond to and benefit from UDCA-treatment, remains an unmet
need. In all three diseases, clarification of the optimal approach for
non-invasive screening for cirrhosis, indicating the need for
hepatocellular carcinoma (HCC) and varices screening, is needed.
It is unclear how widespread is the awareness of IgG4-RD and its
potential as a diagnostic tool in patients with obstructive chole-
static features and/or bile duct-associated mass lesions. This
may significantly limit the reach of effective treatment.
In a setting where only a single approach to therapy exists for
each of these diseases, a conventional approach around simply
using first-line therapies as widely as possible is reasonable. This
approach will not, however, provide the sophisticated level of
treatment evolution that will be necessary in the future. As sec-
ond-line therapies become available in PBC shortly, and in AIH
in the future, it is needed to develop paradigms to identify
patients who will benefit from such second-line therapy in a
way that does not lead to unacceptable geographical variation
in therapy reach. Autoimmune liver diseases, each of which is a
common rare disease, all represent paradigms for the challenge
of delivering effective therapy, using structured models in prac-
tice. Approaches developed in optimizing liver disease may have
applicability well beyond this area, making AILD an important
test bed for the management of therapy delivery.Financial support
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